Cardinal Health, Inc. raised its earnings guidance for fiscal year 2024. For the period, the company expects non-GAAP diluted earnings per share attributable to $7.30 to $7.40, from $7.20 to $7.35. This guidance includes an update to the company?s Pharmaceutical and Specialty Solutions segment profit outlook to 8.5% to 9.5% growth, from 7% to 9% growth.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
104.4 USD | +0.27% |
|
+3.74% | +3.54% |
06-14 | Merit Medical is recalling unauthorized plastic syringes, US FDA says | RE |
06-14 | Deutsche Bank Adjusts Cardinal Health Price Target to $115 From $110 | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.54% | 25.42B | |
+30.30% | 78.41B | |
+6.85% | 8.86B | |
+13.45% | 8.7B | |
-30.05% | 6.99B | |
+17.70% | 5.34B | |
+1.92% | 4.15B | |
-7.07% | 3.42B | |
+9.54% | 3.26B | |
+1.49% | 3.07B |
- Stock Market
- Equities
- CAH Stock
- News Cardinal Health, Inc.
- Cardinal Health, Inc. Raises Its Earnings Guidance for Fiscal Year 2024